Alembic Pharmaceuticals Ltd today announced that the company has received approval from the US Food & Drug Administration (USFDA) to sell a generic alternative to Novartis Pharmaceuticals’ allergic conjunctivitis treatment Patanol Ophthalmic Solution.
This is first ophthalmic dosage form approval for Alembic pharmaceuticals Limited.
The drug, olopatadine hydrochloride ophthalmic solution, has an estimated market size of US$ 61 million for twelve months ending December 2017.
With this, Alembic has a cumulative total of 83 generic approvals, including 13 tentative approvals in the US.
Allergic conjunctivitis is an eye inflammation caused by an allergic reaction to substances like pollen, dust or spores.
The condition results in the swelling of the conjunctiva membrane in the eye.